Gree Real Estate plans to make USD1.726b strategic investment in Kehua Bio

On May 10, Gree Real Estate (600185) issued an announcement of an asset acquisition. The announcement shows that a wholly-owned subsidiary of the company plans to purchase 18.63% stake of Kehua Bio (002022) held by League Agent (HK) Limited through an agreement, with approximately 1.726 billion yuan.

On May 10, Gree Real Estate (600185) issued an announcement of an asset acquisition. The announcement shows that a wholly-owned subsidiary of the company plans to purchase 18.63% stake of Kehua Bio (002022) held by League Agent (HK) Limited through an agreement, with approximately 1.726 billion yuan.

According to the above plan, Gree Real Estate will become the largest shareholder of Kehua Bio after completing the transaction.

Kehua Bio has been focusing in the field of biomedicine for more than 30 years, and has great strength. In the medical circle, Kehua Bio is widely known for its in-vitro diagnostic technology.

It is one of the few companies in China that can provide fully automated and flexible flux detection system solutions and supply capabilities in molecular, biochemical, and immunological fields.

Kehua Bio’s core strengths are concentrated in the three segments of biochemical, immunological and molecular diagnostics. Its business covers the entire IVD industry chain of raw material R&D and production, instruments and reagents R&D, channel distribution etc. It has complete medical diagnostic products and overall solutions.

Kehua Bio has also achieved a lot in the international market, with its products exported to more than 30 countries and regions overseas.

Disclaimer: This is an article created by Michael Liang for Chinasdg.org. You can find the original article here: https://chinasdg.org/2020/05/24/gree-real-estate-plans-to-make-usd1-726b-strategic-investment-in-kehua-bio/.

Leave a Reply

Your email address will not be published. Required fields are marked *